T2	condition 102 142	chemotherapy-induced nausea and vomiting
T3	ethinicity 146 153	Chinese
T4	eligibility 389 502	chemotherapy-naive Chinese breast cancer patients who were planned for (neo)adjuvant doxorubicin/cyclophosphamide
T8	total-participants 914 917	120
T9	outcome 1029 1057	rates of "Complete Response"
T10	iv-bin-percent 1081 1086	65.0%
T11	cv-bin-percent 1090 1095	38.3%
T12	outcome 1096 1117	in the overall period
T13	iv-bin-percent 1132 1137	70.0%
T14	cv-bin-percent 1141 1146	51.7%
T15	outcome 1147 1166	in the acute period
T16	iv-bin-percent 1184 1189	92.9%
T17	cv-bin-percent 1193 1198	74.2%
T18	outcome 1199 1220	in the delayed period
T19	outcome 1280 1328	rates of "No significant nausea" and "No nausea"
T20	outcome 1444 1479	abnormalities in glucose and lipids
T21	control 51 79	standard antiemetic regimens
T1	intervention 22 43	olanzapine-containing
